摘要
目的:探讨水林佳治疗非酒精性脂肪肝的疗效。方法:随机选择非酒精性脂肪肝患者90例,试验组46例,服用水林佳105mg,3次/日;对照组44例,口服硫普罗宁100 mg,3次/日,观察期为3个月。治疗前后检测肝转氨酶、血胆固醇、甘油三酯、肝纤维谱及超声影像变化。同时观察两组患者用药期间的不良反应。结果:治疗结束时,试验组ALT、AST、TC、TG及HA、LN、PC-Ⅲ均明显下降,肝脏影像学也有明显改善。对照组虽ALT、AST有所下降,但HA、LN、PC-Ⅲ和肝脏影像学无明显改善。观察期间两组均未出现明显不良反应。结论:水林佳具有保肝、降血脂、改善肝纤维化的作用,对非酒精性脂肪肝有治疗作用。
Objective：To assess the clinical efficacy of compound silibin-phosphatidylcholine in patients with non-alcoholic fatty liver disease.Methods：90 patients with non-alcoholic fatty liver disease （NAFLD）（abnormal ALT/AST level）were randomly divided into trial group treated with compound silibin-phosphatidylcholine and control group treated with tiopronin tablets respectively for consecutive 3 months.Before and 12 weeks after treatment,the changes of serum transaminase level （ALT/AST） ,cholesterol （TC）,triglyceride（TG）, hepatic fibrosis indicators and ultrasonic image were detected respectively. Side effect was also observed during the experiment.Results： The levels of serum ALT/AST were all obviously reduced at the end point compared with the baseline in both groups. TC ,TG and hepatic fibrosis indicators were significantly reduced in trial group, but was not in control group. The improvement rate of ultrasonic image in trial group was more higher than that in control group and no severe side effect occurred during the experiment in both groups.Conclusion：Compound silibin-phosphatidylcholine has significant therapeutic effect on NAFLD,which shows significant effect in improving the serum parameters of liver function, lipid, hepatic fibrosis indicators and ultrasonic image.
出处
《现代医药卫生》
2008年第13期1921-1922,共2页
Journal of Modern Medicine & Health
关键词
水林佳
脂肪肝
治疗
Compound silibin-phosphatidylcholine
Fatty liver
Therapy
